Rachid Baz, MD, discusses the importance of educating patients about potential adverse effects associated with multiple myeloma treatments.
Rachid Baz, MD
Advertisement
Articles by Rachid Baz, MD
Rachid Baz, MD, discusses findings from an analysis of cytopenias and infections in patients with multiple myeloma enrolled in the KarMMa-3 trial.
Rachid Baz, MD, discusses the use of idecabtagene vicleucel vs standard regimens in triple-class–exposed, relapsed/refractory multiple myeloma.
Rachid Baz, MD, discusses the role of alkylating agents in relapsed/refractory multiple myeloma.
Rachid Baz, MD, discusses the utility of venetoclax in patients with heavily pretreated multiple myeloma.
Rachid Baz, MD, associate member, head of the Myeloma Section at Moffitt Cancer Center, discusses the potential use of selinexor (KPT-330) in patients with multiple myeloma.
Rachid Baz, MD, hematologist and medical oncologist, Moffitt Cancer Center, discusses how treatment approaches vary for patients with multiple myeloma.
Advertisement
Latest Updated Articles
Dr. Baz on the Utility of Venetoclax in Heavily Pretreated Multiple MyelomaPublished: September 29th 2021 | Updated:
Dr Baz on the Incidence of AEs With Ide-Cel in Triple-Class–Exposed Multiple MyelomaPublished: February 16th 2024 | Updated:
Dr Baz on the Background of the KarMMa-3 Trial in Relapsed/Refractory Multiple MyelomaPublished: January 9th 2024 | Updated:
Dr. Baz on Varying Treatment Approaches for Patients With Multiple MyelomaPublished: May 26th 2017 | Updated:
Dr. Baz on Selinexor in Multiple MyelomaPublished: September 5th 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis
5